Stifel Nicolaus Trims Zentalis Pharmaceuticals (NASDAQ:ZNTL) Target Price to $10.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its target price decreased by Stifel Nicolaus from $32.00 to $10.00 in a research report report published on Tuesday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock. Several other research analysts have also weighed in on ZNTL. Wells Fargo & Company lowered Zentalis […]

Leave a Reply

Your email address will not be published.

Previous post CIBC Downgrades Canadian Western Bank (TSE:CWB) to Tender
Next post Needham & Company LLC Reaffirms Hold Rating for Cognyte Software (NASDAQ:CGNT)